o-(β-Hydroxyethyl)-rutoside-mediated Protection of Renal Injury Associated with cis-Diamminedichloroplatinum(II)/Hyperthermia Treatment

A bioflavonoid, o-(β-hydroxyethyl)-rutoside, has been investigated for its potential to increase the therapeutic index of the combined treatment modalities of whole body hypothermia (WBH) (41.5°C) and chemotherapy (cisplatin) in studies utilizing a transplantable fibrosarcoma solid tumor model in Fischer rats. When whole body WBH was induced 45 min after cisplatin administration, a significantly increased tumor growth delay was noted beyond that achieved by either treatment modality alone. The combination of WBH and cisplatin treatments, however, produced an unacceptable increase in renal injury. o-(β-Hydroxyethyl)-rutotoside administration was found to effectively block the renal injury without interfering with the antitumor efficacy of the combined regimen. Potential explanations for the ability of o-(β-hydroxyethyl)-rutoside to affect the increase in WBH-cisplatin therapeutic regimen are discussed.